NCT00582673View on ClinicalTrials.gov

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

PHASE2CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2008

Conditions

Parkinson's Disease

Interventions

DRUG

AFQ056

DRUG

Placebo

Trial Locations (5)

Unknown

Novartis Investigator Site, Dresden

Novartis Investigator Site, Kassel

Novartis Investigator Site, Leun

Novartis Investigator Site, Marburg

Novartis Investigator Site, Tübingen

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY